Day: November 19, 2021

Uponor Corporation ANNOUNCEMENT 19.11.2021          Uponor Corporation: SHARE REPURCHASE 19.11.2021     In the Helsinki Stock Exchange         Trade date 19.11.2021  Bourse trade Buy  Share UPONOR  Amount 39,000 SharesAverage price/ share 21.9730 EURTotal cost 856,947.00 EUR          Uponor Corporation now holds a total of 557 671 sharesincluding the shares repurchased on 19.11.2021          On behalf of Uponor Corporation         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For more information, please contact:  Uponor Corporation    Susanna Inkinen    Vice President, Communications and Corporate ResponsibilityTel. +358 20 129 2081         www.uponorgroup.com       AttachmentUponor_19.11_trades ...

Suominen Corporation ANNOUNCEMENT 19.11.2021          Suominen Corporation: SHARE REPURCHASE 19.11.2021     In the Helsinki Stock Exchange         Trade date 19.11.2021  Bourse trade Buy  Share SUY1V  Amount 10,000 SharesAverage price/ share 4.9101 EURTotal cost 49,101.00 EUR          Suominen Corporation now holds a total of 738 561 sharesincluding the shares repurchased on 19.11.2021          On behalf of Suominen Corporation       Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For additional information, please contact:  Toni Tamminen, CFO, Suominen Corporation  tel. +358 (0)10 214 3051         www.suominen.fi    AttachmentSuominen 19.11 trades

November 19, 2021Announcement no. 23 In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients In July 2021, BioPorto A/S (BioPorto) initiated a dialogue with the US Food and Drug Administration (FDA) on a potential Emergency Use Authorization (EUA) of an NGAL assay for use in predicting the need for renal replacement therapy in COVID-19 patients. The dialogue was based on results from an ELISA and dipstick study of NGAL to screen for renal failure in COVID-19 patients conducted by clinical researchers at Columbia University’s Irving Medical Center, reporting a 97% negative predictive value for the need of renal replacement therapy. This week, the FDA provided guidance to all In-vitro Diagnostics...

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. This notice is published with reference to the initial public offering of the shares of Enefit Green AS (the “Company”) and should be read in conjunction with the Company’s prospectus registered on 4 October 2021 and the pricing statement published on 15 October 2021. The Company hereby gives notice that Swedbank AS, acting as stabilising manager, undertook no stabilisation transactions during the stabilising period in relation to the following securities:Company: Enefit Green ASSecurities: Ordinary...

Tulsa, OK, Nov. 19, 2021 (GLOBE NEWSWIRE) — Renavotio, Inc. (OTCQB: RIII) (the “Company”), an infrastructure investment company focused on opportunities, including medical protective equipment, 5G, ISP, utility construction, utility management, IoT, water, waste management technology, and related industries, announced it has secured an initial order of  $300,000 from an overseas client of medical examination gloves and has increased its on hand inventory of Personal Protective Equipment (“PPE”) in preparation for the upcoming winter season and potential Covid surge. The Company has been increasing its inventory levels of other essential PPE such as gowns, and 100% nitrile medical examination gloves. The Company is focused on both made in the USA products and overseas factory direct partnerships with multiple  Personal Protective...

See attachmentAttachmentManagers transaction – LB

TULSA, OK, Nov. 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – AppSwarm, Corp. (OTC: SWRM), a software development company and aggregator of mobile applications, announced the formation of Tulsalabs aerospace division focused on commercial and military projects. TulsaLabs announces the launch of its aviation division to develop and assist start-ups in the aerospace industry to set-up operations in Oklahoma. The aerospace division will be focused on:Assist startups of advanced technologies such as additive technologies, batteries, electric propulsion, commercial space, unmanned systems. Work with academic and university-led organizations to develop aerospace and defense industry applications of the future. Develop testing facility and research business center focused on commercial and military aerospace and space technologies....

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC®) protein degrader, will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021. ARV-471 is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Presentation details are as follows: Abstract Title: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2-...

BROOKINGS, S.D., Nov. 19, 2021 (GLOBE NEWSWIRE) — Daktronics, Inc. (Nasdaq – DAKT) today announced that its Board of Directors approved an amendment to its Rights Agreement, extending its expiration to November 19, 2024 and changing the exercise price to $20.00. Daktronics believes that the rights agreement enables its Board to be in a better position to perform its fiduciary duties and help the Board to protect shareholders against abusive takeover tactics that may be used to gain control of the company without paying a price that is in the best interest of all shareholders and other stakeholders. The rights are designed to enable Daktronics shareholders to realize the full long-term value of their investment and to provide for fair and equal treatment of all shareholders if an unsolicited attempt is made to acquire Daktronics....